Post

Encouraging results for CAR-T in recurrent glioblastoma: intracranial B7-H3 CAR-T (TX103) was well tolerated in a Phase 1 trial (n=15), with no DLTs. Median OS reached 19.1 months, with 66.7% alive at 12 months and one sustained complete response. Phase 2 warranted. #CARTcells buff.ly/1hWb3c9